Design, Synthesis and Antifungal Activity of 1,2,4-Triazole/ or 1,3,4- Oxadiazole-ciprofloxacin hybrids | ||||
Journal of advanced Biomedical and Pharmaceutical Sciences | ||||
Article 5, Volume 1, Issue 2, October 2018, Page 78-84 PDF (932.62 K) | ||||
Document Type: Short Communication. | ||||
DOI: 10.21608/jabps.2018.3774.1013 | ||||
View on SCiNiTO | ||||
Authors | ||||
Hend A. A. Ezelarab1; Heba A. Hassan1; Samar H. Abbas 1; Rehab M. Abd El-Baky2; Gamal El-Din A. Aburahama 1 | ||||
1Department of Medicinal Chemistry, Faculty of Pharmacy, Minia University, 61519-Minia, Egypt | ||||
2Department of Microbiology, Faculty of Pharmacy, Minia University, 61519-Minia, Egypt | ||||
Abstract | ||||
Due to the rapid development of fungal strains resistance, there is become great demand of newer agents that can withstand these resistant strains. This study involves design and synthesis of ciprofloxacin-triazole or ciprofloxacin-oxadiazole hybrids as potential antifungal agents for the purpose of synergism. Results showed that combination of 1,2,4-triazole or its bioisoster oxadiazole with ciprofloxacin can enhance antifungal activity against Candida albicans. The triazole hybrid 11 experienced comparable antifungal activity with itroconazole (MIC = 10.23 and 11.22 µg/mL, respectively). Molecular docking study showed that hybrid 11 can bind to the active site of lanosterol 14-α-demethylase CYP51 with reasonable docking scores. | ||||
Keywords | ||||
Fluoroquinolones; Azoles; Hybrids; Antifungal; Molecular docking | ||||
Statistics Article View: 755 PDF Download: 968 |
||||